|
type |
publicatie |
| 55 |
Artikel |
Smith A, Bird G.
The compatibility of diazepam with infusion fluids and their containers.
J Clin Hosp Pharm 1982 ; 7: 181-186. |
| 58 |
Artikel |
Parker WA.
Physical compatibility of ranitidine HCl with preoperative injectable medications.
Can J Hosp Pharm 1985 ; 38: 160-161. |
| 59 |
Artikel |
Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
| 73 |
Artikel |
Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159. |
| 93 |
Artikel |
Hutchings SR, Rusho WJ, Tyler LS.
Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery.
Am J Health-Syst Pharm 1996 ; 53: 2185-2188. |
| 190 |
Artikel |
Lee MG.
Sorption of four drugs to polyvinyl chloride and polybutadiene intravenous administration sets.
Am J Hosp Pharm 1986 ; 43: 1945-1950. |
| 198 |
Artikel |
Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520. |
| 226 |
Artikel |
Walker SE, DeAngelis C, Iazzetta J.
Stability and compatibility of combinations of hydromorphone and a second drug.
Can J Hosp Pharm 1991 ; 44: 289-295. |
| 266 |
Artikel |
Patel PR.
Compatibility of meropenem with commonly used injectable drugs.
Am J Health-Syst Pharm 1996 ; 53: 2853-2855. |
| 299 |
Artikel |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
| 300 |
Artikel |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
| 348 |
Artikel |
Hancock BG, Black CD.
Effect of a polyethylene-lined administration set on the avaibility of diazepam injection.
Am J Hosp Pharm 1985 ; 42: 335-339. |
| 350 |
Artikel |
Martens HJ, De Goede PN, Van Loenen AC.
Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers.
Am J Hosp Pharm 1990 ; 47: 369-373. |
| 351 |
Artikel |
Yliruusi JK, Uotila JA, Kristoffersson ER.
Effect of flow rate and type of IV container on adsorption of diazepam to IV administration systems.
Am J Hosp Pharm 1986 ; 43: 2795-2799. |
| 352 |
Artikel |
Yliruusi JK, Uotilo JA, Kristoffersson ER.
Effect of tubing length on adsorption of diazepam to polyvinyl chloride administration sets.
Am J Hosp Pharm 1986 ; 43: 2789-2794. |
| 402 |
Artikel |
Savitsky ME.
Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 820-821. |
| 476 |
Artikel |
Knapp AJ, Mauro VF, Alexander KS.
Incompatibility of ketorolac tromethamine with selected postoperative drugs.
Am J Hosp Pharm 1992 ; 49: 2960-2962. |
| 496 |
Artikel |
Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746. |
| 616 |
Artikel |
Jump WG, Plaza VM, Poremba A.
Compatibility of nalbuphine hydrochloride with other preoperative medications.
Am J Hosp Pharm 1982 ; 39: 841-843. |
| 621 |
Artikel |
Yliruusi JK, Sothmann AG, Laine RH, Rajasilta RA, Kristoffersson ER.
Sorptive loss of diazepam and nitroglycerin from solutions to three types of containers.
Am J Hosp Pharm 1982 ; 39: 1018-1021. |
| 660 |
Artikel |
Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232. |
| 711 |
Artikel |
Cloyd JC, Vezeau C, Miller KW.
Avaibility of diazepam from plastic containers.
Am J Hosp Pharm 1980 ; 37: 492-496. |
| 712 |
Artikel |
Parker WA, MacCara ME.
Compatibility of diazepam with intravenous fluid containers and administration sets.
Am J Hosp Pharm 1980 ; 37: 496-500. |
| 730 |
Artikel |
Allen LV, Saul Levinson R, Phisutsinthop D.
Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets.
Am J Hosp Pharm 1977 ; 34: 939-943. |
| 731 |
Artikel |
Morris ME.
Compatibility and stability of diazepam injection following dilution with intravenous fluids.
Am J Hosp Pharm 1978 ; 35: 669-672. |
| 921 |
Artikel |
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292. |
| 939 |
Artikel |
Gilbar PJ, Groves CF.
Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection.
Aust J Hosp Pharm 1994 ; 24: 167-170. |
| 1041 |
Artikel |
Hasegawa GR, Eder JF.
Visual compatibility of dobutamine hydrochloride with other injectable drugs.
Am J Hosp Pharm 1984 ; 41: 949-951. |
| 1057 |
Artikel |
Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207. |
| 1067 |
Artikel |
Zeidler C, Dettmering D, Schrammel W, Spieteller M.
Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers.
EJHP 1999 ; 5: 106-110. |
| 1102 |
Artikel |
Cossum PA, Roberts MS.
Availability of isosorbide dinitrate, diazepam and chlormethiazole, from i.v. delivery systems.
Eur J Clin Pharmacol 1981 ; 19: 181-185. |
| 1173 |
Artikel |
Kowaluk EA, Roberts MS, Blackburn HD, Polack AE.
Interactions between drugs and polyvinyl chloride infusion bags.
Am J Hosp Pharm 1981 ; 38: 1308-1314. |
| 1182 |
Artikel |
Mason NA, Cline S, Hyneck ML, Berardi RR, Ho NFH, Flynn GL.
Factors affecting diazepam infusion: solubility, administration-set composition, and flow rate.
Am J Hosp Pharm 1981 ; 38: 1449-1454. |
| 1199 |
Artikel |
Smith FM, Nuessle NO.
Stability of diazepam injection repackaged in glass unit-dose syringes.
Am J Hosp Pharm 1982 ; 1687-1690. |
| 1200 |
Artikel |
Chaudry IA, Bruey KP, Hurlburt LE, Oden EM.
Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives.
Am J Hosp Pharm 1981 ; 38: 1737-1742. |
| 1232 |
Artikel |
Beatson C, Taylor A.
A physical compatibility study of furosemide & flucloxacillin injections.
Br J Pharm Pract 1987 ; 9: 223-226, 236. |
| 1269 |
Artikel |
DeMuynck C, De Vroe C, Remon JP, Colardyn F.
Binding of drugs to end-line filters: a study of four commonly administered drugs in intensive care units.
J Clin Pharm Ther 1988 ; 13: 335-340. |
| 1271 |
Artikel |
Mathot F, Bonnard J, Paris P, Bosly J.
Reliable continuous IV perfusion system for diazepam.
J Pharm Belg 1982 ; 37: 153-156. |
| 1366 |
Artikel |
Jeglum EL, Winter E, Kotos M.
Nafcillin sodium incompatibility with acidic solutions.
Am J Hosp Pharm 1981 ; 38: 462,464. |
| 1424 |
Artikel |
Gottwald MD, Akerd LC, Liu PK, Orsulak PJ, Corry M, Bacchetti P, Fields SM, Loxenstein DH, Alldredge BK.
Prehospital stability of diazepam and lorazepam.
Am J Emerg Med 1999 ; 17: 333-337. |
| 1438 |
Artikel |
Souney PF, Solomon MA, Stancher D.
Visual compatibility of cimetidine hydrochloride wih common preoperative injectable medications.
Am J Hosp Pharm 1984 ; 41: 1840-1841. |
| 1472 |
Artikel |
Salomies HEM, Heinonen RM, Toppila MAI.
Sorptive loss of diazepam, nitroglycerin and warfarin sodium to polypropylene-lined infusion bags (Softbags).
Int J Pharm 1994 ; 110: 197-201. |
| 1512 |
fabrikant |
Tirofiban (Aggrastat®) - Summary of Product Characteristics
Beacon Pharmaceuticals Ltd 2015 |
| 1522 |
fabrikant |
Macoflex N®
Maco Pharma 2001 |
| 1603 |
Artikel |
Bergquist PA, Manas D, Hunke WA, Reed RA.
Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs.
Am J Health-Syst Pharm 2001 ; 58: 1218-1223. |
| 1625 |
Artikel |
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321. |
| 1662 |
Artikel |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37. |
| 1712 |
Artikel |
Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233. |
| 1713 |
Artikel |
Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315. |
| 1721 |
Artikel |
Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72. |
| 1803 |
Artikel |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85. |
| 1925 |
Artikel |
Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519. |
| 1960 |
Artikel |
Kambia NK, Dine T, Dupin-Spriet T, Gressier B, Luycks M, Goudaliez F, Brunet C.
Compatibility of nitroglycerin, diazepam and chlorpromazine with a new multilayer material for infusion containers.
J Pharm Biomed Anal 2005 ; 37: 259-264. |
| 1974 |
Artikel |
Chandler SW, Trissel LA, Weinstein SM
Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility.
J Pain Symptom Manage 1996 ; 12, 3: 168-171. |
| 2087 |
Artikel |
Ferreira E, Forest JM, Hildgen P.
Compatibility of dimenhydrinate injectable by Y administration.
Pharmactuel 2004 ; 37: 17-20. |
| 2090 |
Artikel |
Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196. |
| 2262 |
Artikel |
Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265. |
| 2269 |
Artikel |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
| 2324 |
Artikel |
Treleano A, Wolz G, Brandsch R, Welle F.
Investigation into the sorption of nitroglycerin and diazepam into PVC tubes and alternative tube materials during application
Int J Pharm 2009 ; 369, 1-2 : 30-37 |
| 3012 |
Artikel |
Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220. |
| 3184 |
fabrikant |
Hyaluronidase (Hyalase®) - Summary of Product characteristics.
CP Pharmaceuticals 2005 |
| 3216 |
Artikel |
Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18 |
| 3249 |
Artikel |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 3332 |
fabrikant |
Tigecycline (Tigacyl®) - Summary of Product characteristics
Pfizer 2012 |
| 3408 |
Artikel |
Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21. |
| 3474 |
fabrikant |
Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009 |
| 3501 |
fabrikant |
Ketamine hydrochloride (Ketalar®) - Summary of Product Characteristics
Pfizer 2011 |
| 3521 |
fabrikant |
Tramadol® - Summary of Product Characteristics.
Beacon Pharmaceuticals 2012 |
| 3539 |
fabrikant |
Bivalirudin (Angiox®) - Summary of Product Characteristics.
The Medecines Company 2013 |
| 3540 |
fabrikant |
Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010 |
| 3560 |
fabrikant |
Linezolid (Zyvox®) - Summary of Product Characteristics
Pharmacia 2013 |
| 3564 |
fabrikant |
Rocuronium B Braun - Résumé des caractéristiques du produit.
B Braun 2012 |
| 3571 |
Artikel |
Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M.
Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration.
Hosp Pharm 2014 ; 49, 1: 42-47. |
| 3599 |
fabrikant |
Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics
Amco Amdipharm Mercry 2013 |
| 3607 |
fabrikant |
Esmolol hydrochloride for injection - Summary of Product Characteristics
AOP Orphan Pharmaceuticals AG 2013 |
| 3614 |
fabrikant |
Nicardipine Injection - Summary of Product Characteristics
American Regent Inc 2013 |
| 3617 |
fabrikant |
Hyaluronidase (Hyalase®) - Summary of Product Characteristics
Wockhardt 2011 |
| 3672 |
fabrikant |
Nalbuphine Mylan - Résumé des caractéristiques du produit
Mylan SAS 2016 |
| 3766 |
Artikel |
Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165. |
| 3767 |
Artikel |
Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172. |
| 3824 |
Artikel |
Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98 |
| 3885 |
Artikel |
Su-Eon Jin, Siwon You, Seungho Jeon, Sung-Joo Hwang.
Diazepam sorption to PVC- and non-PVC-based tubes in administration sets with quantitative determination using a high-performance liquid chromatographic method.
Int J Pharm 2016 ; 506 : 414-419. |
| 3932 |
fabrikant |
Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit
Serb Laboratoire 2015 |
| 3941 |
fabrikant |
Nicardipine - Summary of Product Characteristics
Concordia International 2017 |
| 3964 |
Artikel |
Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33. |
| 4154 |
fabrikant |
Bleomycin sulfate- Summary of Product Characteristics
Accord Health Care 2018 |
| 4319 |
Artikel |
Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337. |
| 4428 |
Artikel |
Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J.
Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma.
J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132. |
| 4435 |
Artikel |
Hanifah S, Nugroho B.H, Chabib L.
Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection.
Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27. |
| 4603 |
Artikel |
Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234. |
| 4650 |
fabrikant |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021 |
| 4700 |
fabrikant |
Esketamine 25 mg/mL solution for injection/infusion. - Summary of Product Characteristics
AS Kalceks 2022 |
| 4742 |
Artikel |
Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255. |
